title: Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.
authors.forename: Marco
authors.initials: M
authors.lastname: Maria Lizzio
authors.forename: Giusy
authors.initials: G
authors.lastname: Peluso
authors.forename: Angelo
authors.initials: A
authors.lastname: Zoli
authors.forename: Elisa
authors.initials: E
authors.lastname: Gremese
authors.forename: Barbara
authors.initials: B
authors.lastname: Tolusso
authors.forename: GianFranco
authors.initials: G
authors.lastname: Ferraccioli
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D010352:Patient Dropouts; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D000069285:Infliximab